Sign in
CompletedPhase 3

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

Key facts

Who runs it
Sint Maartenskliniek
Where
Netherlands7 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
114 people enrolled
Started
1 Feb 2023
Ended
29 Oct 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Rituximab
  • Placebo
Record updated
3 February 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Polymyalgia rheumatica diagnosis fulfilling the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria
  • Diagnoses less than 12 weeks ago
  • Glucocorticoid treatment less than 8 weeks and with dose equivalent of prednisolone ≤ 30 mg/day
  • Informed consent

Who cannot take part

  • treatment with systemic immunosuppressants (other than glucocorticoids) 3 months prior to inclusion
  • (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases
  • concomitant conditions that might significantly interfere with PMR pain or movement evaluation as judged by the investigator
  • previous hypersensitivity for RTX or contra-indications to RTX

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Though promising, the short study duration and small sample size require further confirmation. Therefore a larger randomised controlled trial with longer follow up will be performed on RTX efficacy on glucocorticoid free remission in newly diagnosed PMR patients during glucocorticoid taper.

The 2 groups in the trial

  • RituximabTreatment being tested

    1000mg rituximab intravenously once

  • PlaceboPlacebo, for comparison

    0mg rituximab (placebo) intravenously once

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica
Publications
Record updated
3 February 2026